Biopharmaceutical company Ribomic and biotechnology company Evec have both entered a research agreement.
The two partners will jointly develop an antibody purification technology using aptamer as part of the agreement.
Puridify and GlaxoSmithKline have entered an 18-month collaboration agreement to evaluate the FibroSelect purification technology.
The agreement enables the two partners to develop a package to evaluate the importance of nanofibres in toxicology and clinical manufacture using Puridify’s FibroSelect purification technology.
Ferring Pharmaceuticals and MetaboGen have entered a research agreement to develop a novel treatment for intrahepatic cholestatis of pregnancy (ICP).
According to the agreement, MetaboGen’s concept for effects of bacteria in the gut on ICP will be used to develop an exploratory study, which will be funded by Ferring Pharmaceuticals.
The agreement enables the two partners to demonstrate the difference in the microbiome patterns in healthy women and in women with ICP.
Blueprint Medicines plans to raise gross proceeds of $125m through the underwritten public offering of common stock shares.
Goldman, Sachs & Co, Morgan Stanley, and Cowen and Company are acting as joint book-running managers for the offering.
The company plans to use the funds to advance the clinical trials of BLU-285 in advanced gastrointestinal stromal tumours, to advance clinical trials of BLU-667 in RET-driven cancers and to increase working capital and other general corporate purposes.
Prolacta Biosciences has raised $35m in a mezzanine financing round led by Essex Woodlands and co-led by Aisling Capital and Health Evolution Partners.
The company plans to use the proceeds to expand its presence in Europe, to advance the clinical trials for the development of human milk-based nutritional products and evaluate the role of human milk oligosaccharides (HMOs) to treat different microbiome related diseases.
Image: Puridify and GlaxoSmithKline have entered an 18-month collaboration agreement. Photo: Courtesy of Ian Wilson.